Introduction
Th e adipose tissue secretes several bioactive mediators that infl uence infl ammation, insulin resistance, diabetes, atherosclerosis, and several other pathologic states besides the regulation of body weight. Th ese mediators are mostly proteins and are termed 'adipocytokines' comprising adiponectin, resistin, visfatin, retinol binding protein-4, and leptin [1, 2] .
Nicotinamide phosphoribosyltransferase (visfatin), an enzyme involved in the NAD+ salvage pathway, has been shown to help in the regulation of glucose homeostasis. It is a highly conserved, 52 kDa protein found in living species from bacteria to humans. It is an adipokine produced and secreted primarily by visceral white adipose tissue. Visfatin is also produced by endotoxin-stimulated neutrophils and inhibits neutrophil apoptosis through its antiapoptotic activity mediated by caspase 3 and caspase 8. Nicotinamide phosphoribosyltransferase is a pleotropic protein with multiple functions in a variety of physiological processes; their dysregulations have been implicated in the pathogenesis of a number of human diseases or conditions such as acute lung injury, aging, atherosclerosis, cancer, diabetes, rheumatoid arthritis, and sepsis [3, 4] . 
Correlation of serum visfatin level with chest pain scoring as an indication of myocardial ischemia in chronic kidney disease patients
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Background
Nicotinamide phosphoribosyltransferase (Visfatin), an enzyme involved in the NAD+ salvage pathway, has been shown to help in the regulation of glucose homeostasis. It is a highly conserved, 52 kDa protein found in living species from bacteria to humans. It is an adipokine produced and secreted primarily by adipose tissue. Chronic kidney disease (CKD) and end-stage renal disease patients showed increased cardiovascular mortality, and vascular events account for more than half of the deaths in this population. Myocardial ischemia is a consequence of coronary heart disease. Recent studies found that with increasing visfatin levels, CKD patients have a larger number of vessels with stenosis and a higher likelihood of coronary artery disease.
Research design and methods
The current prospective study includes 137 CKD patients and patients with chest pain (CP), as well as 20 patients as controls. Patient data included age, sex, comorbidities, smoking status, weight, height, and BMI, calculated using the equation: BMI = weight (kg)/height (m 2 ). Estimated glomerular fi ltration rate was calculated using the modifi ed Modifi cation of Diet in Renal Disease equations; in addition, enzyme-linked immunosorbent assay was used to estimate serum visfatin levels, and CP was assessed through a modifi cation of the master questionnaire.
Results
All patients had signifi cantly (P < 0.05) higher serum visfatin levels compared with controls. Patients who had typical anginal CP had signifi cantly (P < 0.05) higher serum visfatin levels compared with those who had atypical anginal or nonanginal CP, with nonsignifi cantly (P > 0.05) higher serum visfatin levels in patients with atypical anginal CP compared with those with nonanginal CP. Moreover, patients with stage 4 CKD had a signifi cantly (P < 0.05) higher serum visfatin level compared with patients with stage 3 CKD.
Conclusion
It could be concluded that patients with CKD are at an actual risk of developing CP secondary to myocardial ischemic attack, presenting either as typical or as atypical anginal pain. Elevated serum visfatin levels may be the cornerstone for the relationship between CKD and coronary heart disease. Serum visfatin levels in range of 12. 4-16.4 ng/ml could predict the possibility of developing an anginal attack in patients with atypical anginal CP, with high sensitivity and specifi city for diagnosis.
Chronic kidney disease (CKD) and end-stage renal disease (ESRD) patients showed increased cardiovascular mortality, and vascular events account for more than half of the deaths in this population [5] . Myocardial ischemia, a consequence of coronary artery disease, is a major cause of death among patients with ESRD. Th e pathophysiology and clinical presentation of coronary artery disease in ESRD patients seem to diff er from those in non-ESRD patients, with a higher implication of myocardial microvascular disease, a higher mortality rate, fewer myocardial infarctions, less signifi cant coronary stenosis, and low effi cacy of well-established drugs such as statins and angiotensinconverting enzyme inhibitors. Traditional risk factors fail to explain the increased risk for cardiovascular morbidity and mortality in ESRD patients [6] .
Th e current prospective study aimed to estimate the serum visfatin level in CKD patients and in patients who complained of chest pain (CP) and to correlate serum visfatin levels with clinical CP scoring.
Patients and methods
Th e current prospective double-blinded study was conducted at the Departments of Nephrology and Cardiology, Ibn Sina College of Medicine, Jeddah, KSA, from June 2009 until August 2013. After approval of the study protocol by the local ethical committee and obtaining the patients' consent, 137 CKD patients and those who complained of CP were enrolled in the study.
Exclusion criteria included a history of congestive heart failure, defi ned as dyspnea in addition to any two of the following conditions -raised jugular venous pressure, bilateral basilar crackles, pulmonary venous hypertension, interstitial edema on chest radiography (requiring hospitalization or extra-ultrafi ltration), left ventricular ejection fraction less than 35%, and intercurrent or terminal illnesses; history of coronary artery bypass graft surgery; infl ammatory diseases such as infection, sepsis, liver disease, and collagen disease; or steroid use or surgery within 1 month before admission.
Th e study also included 20 age-matched age and sex-matched volunteers free of any form of renal impairment due to cardiac diseases, chosen from among those attending the hospital blood bank for blood donation after passing the preliminary laboratory investigations required for blood donation according to hospital protocol, who served as a control group for serum visfatin levels. , and stage 5 with GFR of less than 15 ml/ min/1.73 m 2 [8] .
All laboratory investigations were performed before the angiographic procedure. After a 12-h fasting period, whole blood samples (10 ml) were obtained from patients and controls, which were collected in a plain tube and allowed to clot; the samples were centrifuged at 5000 rpm for 10 min and serum was separated into two parts: the fi rst part was put in an Eppendorf tube and stored at -80°C until quantitative ELISA estimation of serum visfatin levels (Visfatin C-terminal ELISA kit; Phoenix Pharmaceuticals Inc., Burlingame, Californ ia, USA) [9] ; the other part of the serum was used for estimation of serum levels of triglycerides, total cholester ol, low-density lipoprotein cholester ol, high-density lipoprotein cholester ol (HDL), uric acid, albumin, creatinine, and glucose by standard commercial methods on a parallel, multichan nel analyzer (Hitachi 7170A; Hitachi, Tokyo, Japan).
CP was assessed on the basis of a modifi cation of the Master questionnaire (Fig. 1 ). Typical anginal pain was diagnosed if the following criteria were fulfi lled: Pain is described as a constricting discomfort in the front of the chest or in the neck, shoulders, jaw, or arms; pain is precipitated by physical exertion and relived by rest or glycerin trinitrite administration within about 5 min; patients with typical angina. Patients with pain fulfi lling two of these three criteria were diagnosed as having atypical anginal pain. Patients fulfi lling one criterion or none of the three criteria were diagnosed as having nonanginal pain [10] .
All patients with atypical anginal pain and nonanginal pain were assessed for the risk of developing coronary artery disease within the next 10 years using the Framingham database [11, 12] . Patients with nonanginal pain or atypical anginal pain with a CP score of 10 or lower were assessed for causes of CP other than coronary heart disease (CHD), and those with persistent pain after exclusion or treatment of other causes of CP were assessed using functional imaging or coronary angiography (CA). Patients with typical or atypical anginal pain who had CP scores in range of 11-59 were assigned for functional imaging us ing MRI. Patients with typical or atypical anginal pain with scores f rom 60 to 90 were assigned for diagnostic CA.
Patients with typical anginal pain who scored greater than 90 were assigned to receive treatment for angina until they were stabilized and to undergo diagnostic CA for planning of revascularization (Table 1 ) [13, 14] . and hypertension in 20 patients, and other causes in nine patients; the underlying disease was unknown in 16 patients. Th e mean systolic blood pressure was 137.7 ± 23 mmHg, range: 110-175 mmHg, whereas the mean diastolic blood pressure was 84.5 ± 3.8 mmHg, range: 75-90 mm Hg (Table 2) . Th e mean levels of laboratory data of studied patients are shown in (Table 3) .
Results

Th
Th e mean serum creatinine (S. Cr) level was 2.39 ± 0.53 mg/dl, range: 1.3-4.27 mg/dl; 69 patients (50.6%) had S. Cr levels in the range of 2-2.5 mg/dl; 32 patients had S. Cr levels in the range of 1.5-2 mg/dl, 30 patients had S. Cr levels higher than 2.5 mg/dl, whereas only six patients had S. Cr levels less than 1.5 mg/dl. Fortyseven patients (34.4%) had a mean eGFR of 36.7 ± 6.6 ml/min/1.73 m 2 , range: 30-59 ml/min/1.73 m 2 (CKD stage 3), whereas 90 patients (65.6%) had a mean eGFR of 22.9 ± 4.5 ml/min/1.73 m 2 , range: 15-29 ml/ min/1.73 m 2 (CKD stage 4; Table 4 and Fig. 2 ).
Chest pain questionnai re [10] . Patients distribution according to stage of CKD and their eGFR. CKD, chronic kidney disease; eGFR, estimated glomerular fi ltrati on rate. for diagnostic invasive CA, and four patients with scores of 90 or higher, who were managed as anginal patients and received appropriate management to be further evaluated later using invasive CA to prepare for revascularization surgery (Table 5) .
CP scoring of patients with atypical anginal pain defi ned 12 patients with scores of 10 or lower, who were further evaluated for causes oth er than CAD for their CP, 55 patients with scores in the range of 11-59, who were assigned for functional imaging using MRI, and 28 patients with a score of 60 or higher, who were assigned for diagnostic invasive CA. Patients with nonanginal pain showed mosaic scores, with a mean of 22.4 ± 18.9, range: 5-69, and all were further evaluated for causes other than CAD for their CP. Th us, 57 patients were assigned for functional imaging, 33 patients were assigned for diagnostic invasive CA, 43 patients were evaluated for causes other than CAD for their CP, and four patients were managed as anginal patients (Table 5 ).
All patients with atypical anginal or nonanginal CP were subjected to evaluation of future CHD risk, which was found to be correlated with the scores of the CP questionnaire, with a possible higher risk for developing CHD within 10 years among those had CP scores of 60 or higher compared with those who had atypical anginal pain with CP scores of less than 60 and those who had nonanginal CP (Table 6 and Fig. 3 ).
All patients had signifi cantly (P < 0.05) higher serum visfatin levels compared with controls. Patients with typical anginal CP had signifi cantly (P < 0.05) higher serum visfatin levels compared with those with atypical anginal or nonanginal CP, with nonsignifi cantly Data are presented as means ± SD and number; ranges and percentages are in parenthesis. DBP, diastolic blood pressure; SBP, systolic blood pressure. CP questionnaire and CHD risk scoring of studied patients categorized according pain characters. CHD, chronic heart disease; CP, che st pain.
P atients were categorized according to character of CP as follows: 11 patients (8%) had typical anginal pain, 95 patients (69.4%) had atypical anginal pain, and 31 patients (22.6%) had nonanginal pain. CP scoring of patients with typical anginal pain defi ned two patients with scores less than 60, who were assigned for functional imaging using MRI, fi ve patients with scores in r ange of 60-90, who were assigned (P > 0.05) higher serum visfatin levels in patients with atypical anginal CP compared with those with nonanginal CP (Fig. 4) . Moreover, patients with stage 4 CKD had signifi cantly (P<0.05) higher serum visfatin levels compared with patients with stage 3 CKD (Table 7 and Fig. 5 ).
Th e calculated CP score showed a signifi cant positive correlation with age, male sex, presence of diabetes mellitus, and serum visfatin level, whereas it showed a signifi cant negative correlation with the serum HDL level. Th e serum visfatin level of the studied patients showed a signifi cant positive correlation with male sex, whereas it showed a signifi cant negative correlation with eGFR (Table 8 ).
Evaluation of the serum visfatin level as a hazard function for the possibility of getting a high CP score showed progressively increased cumulative hazard with increasing levels of visfatin (Fig. 6) . Evaluation of the 50th and 75th percentiles of serum visfatin lev els (12.4 and 16.4 ng/ml, respectively) as cutoff points for prediction of high CP scores using receiver-operating characteristic curve analysis showed a wider area under the curve (0.715) for the 50th percentile compared with the 75th percentile (0.661; Fig. 7a and b, respectively) .
Evaluation of both cutoff points revealed a high sensitivity and a negative predictive value for the cutoff Data are presented as means ± SD and number; ranges and percentages are in parenthesis; eGFR, estimated glomerular fi ltration rate. Data are presented as numbers and mean ± SD; percentages and ranges are in parenthesis; CA, coronary angiography; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CP, chest pain; CT, computed tomography. Data are presented as numbers and mean ± SD; percentages and ranges are in parenthesis; CHD, coronary heart disease; CP, chest pain.
Figure 4
Serum ( ± SD) visfatin levels estimated in studied patients categorized according to character of CP and compared with controls. CP, ch est pain.
point 12.4 ng/ml, whereas the cutoff point 16.4 ng/ml had a high specifi city and a positive predictive value, with higher likelihood ratios ( Table 9 ). Th us, serum visfatin level in range of 12.4-16.4 ng/ml is suspicious of having a CHD necessitating either functional imaging or invasive CA.
Discussion
Th e current study provided interesting data on patients with CKD and presenting with CP; fi rst, ∼8% of the studied patients had typical anginal pain that required treatment, without invasive investigations being required in ∼30% of these patients. Second, ∼65% of the studied patients required investigations for possible myocardial ischemia, and 35% of these patients were assigned for invasive CA directly and 65% were assigned for preliminary functional imaging. Th ese fi ndings highlight the necessity for monitoring the myocardial status and function of CKD patients, irrespective of the severity of the disease, as evidenced by the positive nonsignifi cant correlation between CP score, serum creatinine, and eGFR.
Th ird, serum levels of visfatin were signifi cantly higher in studied patients compared controls and were signifi cantly higher in patients with stage 4 CKD compared with those with stage 3 CKD. Th ese fi ndings indicate concomitant elevation of serum visfatin levels with increasing severity of CKD. In contrast, signifi cantly higher serum levels of visfatin were observed in patients with typical anginal CP compared with those with atypical or nonanginal pain, suggesting a relation between elevated serum visfatin levels and an increased risk for myocardial ischemia.
Th us, high serum visfatin levels may be a connecting channel between CKD and CHD, as evidenced by the signifi cant negative correlation between eGFR and serum visfatin levels and the signifi cant positive correlation with CP scores and serum HDL levels, a cardiovascular risk factor. In accordance with this Mean ( ± SD) serum visfatin levels estimated in studied patients categorized according to CKD stage and compared with levels in controls. CKD, chronic kidney disease.
Figure 6
Cumulative hazard function of serum visfatin for the possibility of high CP scores of studied patients. CP, ch est pain. suggestion, Nüsken et al. [15] reported that serum visfatin levels were incre ased in hemodialysis patients compared with controls and dialysis patients; only plasma HDL levels and insulin-treated diabetes mellitus were independently associated with serum visfatin levels. Bessa et al. [16] reported that serum visfatin is strongly associated with endothelial adhesion molecules and the percentage of fl owmediated dilatation, thus suggesting that visfatin is an important promising biomarker for the prediction of endothelial dysfunction. In addition, they suggested that the relationship between visfa tin and IL-6 indicates that circulating visfatin may refl ect the subclinical infl ammatory status, thus concluding that visfatin might be involved in the complex interactions between endothelial dysfunction, infl ammation, and atherosclerosis, leading to future cardiovascular risk in CKD patients.
Recently, Lu et al. [17] found that with increasing visfatin levels, CKD patients had a larger number of vessels with stenosis and a higher likelihood of coronary artery disease, as well as incrementally lower eGFR and serum albumin levels and higher high-sensitivity C-reactive protein and brain natriuretic peptide levels, and concluded that signifi cantly higher plasma visfatin levels in the presence of coronary artery disease suggests that increased plasma visfatin levels may be involved in the pathogenesis of coronary atherosclerosis in CKD patients. Tang et al. [18] found that serum levels of visfatin, IL -6, and CRP were signifi cantly increased in CKD patients compared with age-matched healthy controls, serum visfatin levels increased with the progression of renal dysfunction, patients with carotid artery plaques showed signifi cantly higher levels of visfatin compared with those without plaques, and they showed using multiple regression analysis that the serum visfatin level is an independent risk factor for carotid atherosclerosis; they concluded that the serum level of visfatin should be considered to be a new risk factor for atherosclerosis in CKD.
Statistical analysis of diagnostic cutoff points of serum visfatin levels defi ned a high sensitivity and negative predictive value for the cutoff point 12.4 ng/ml and a high specifi city and positive predictive value with higher likelihood ratios for the cutoff point 16.4 ng/ ml. Th us, patients with serum visfatin levels in range 12.4-16.4 ng/ml are suspected of having a CHD, necessitating further evaluation. In support of the applicability of serum visfatin levels as predictors for cardiovascular lesions, Gunes et al. [19] found that the mean visfatin level was signifi cantly higher in hypertensive patients and in the prehypertensive group than in participants with normal blood pressure, with a signifi cantly positive correlation between visfatin levels and systolic and diastolic blood pressure. Karakan et al. [20] found that the left ventricular mass index was correlated with BMI, systolic blood pressure, and serum visfatin levels, and that on regression an alysis, systolic blood pressure and serum visfatin levels were independent variables aff ecting the left ventricular mass index, but serum visfatin levels might be a more sensitive marker than other evaluations for cardiac performance in nondiabetic peritoneal dialysis Table 9 Correlation coeffi cient 'r' between CP score and serum visfatin levels and demographic, clinical, and laboratory data patients. Moreover, Mazaherioun and colleagues found signifi cantly higher serum visfatin levels in patients with acute myocardial infarction (12.77 ± 8.06 ng/ml) compared with controls (6.57 ± 2.96 ng/ml), and a visfatin level greater than 7.244 ng/ml was found to have a sensitivity of 70% and a specifi city of 75% for predicting acute myocardial infarction.
It could be concluded that patients with CKD are at an actual risk of developing CP secondary to myocardial ischemic attack, presenting either as typical or as atypical anginal pain. Elevated serum visfatin levels may be the cornerstone of the relationship between CKD and CHD. Serum visfatin levels in range 12.4-16.4 ng/ml could predict the possibility of having an anginal attack in patients with atypical anginal CP, with high sensitivity and specifi city for di agnosis.
